Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193232
Status:
COMPLETED
Last Update Posted:
2010-07-28
First Post:
2005-09-12
Brief Title:
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Trial of Weekly Docetaxel and Bortezomib Velcade PS-341 in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of the effectiveness of weekly docetaxelbortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer
Detailed Description:
Upon determination of eligibility patients will be receive
Docetaxel Bortezomib
Patients with objective responses or stable disease will continue treatment for eight courses or until disease progression is documented
Docetaxel Bortezomib
Patients with objective responses or stable disease will continue treatment for eight courses or until disease progression is documented
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IIT16160 | None | None | None |